Market Cap (In CAD)
7.16 Million
Revenue (In CAD)
-
Net Income (In CAD)
-2.29 Million
Avg. Volume
17.59 Thousand
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.06-0.19
- PE
- -
- EPS
- -
- Beta Value
- 0.476
- ISIN
- CA57384M1077
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. J. Roderick Matheson
- Employee Count
- -
- Website
- https://marvelbiotechnology.com
- Ipo Date
- 2021-07-13
- Details
- Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
More Stocks
-
HOOD
-
CRS
-
PMHG
-
4540
-
SMR
-
LIVNLivaNova PLC
LIVN
-
CATGSA Catana Group
CATG
-
PX